A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer is a phase 3 interventional study registered as NCT07213804, led by Eli Lilly and with GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) and Asia-Pacific Gynecologic Oncology Trials, and recruiting when checked on 2026-09-11. Official title: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. Planned enrolment is 1630 participants (estimated). The study started in 2025-10-22 and primary completion is expected in 2028-11. No results have been posted on ClinicalTrials.gov.